AAFP hires Hanaway to succeed Melton

Share this article:
The American Academy of Family Physicians has named ex-Ascend publisher Stephanie Hanaway to lead its titles, taking over for Joetta Melton, who is retiring.

Hanaway becomes publisher, American Family Physician and Family Practice Management, and director of publications. She reports to Michael Springer, VP publishing and communications.
“She has a very diverse background,” said Springer, “with a lot of experience in ancillary products and advance media, and we're delighted to have found her in our own back yard.” AAFP, like Ascend, is located in the Western medical publishing mecca of Overland Park, KS.

Hanaway spent most of her 20-year career in medical publishing at Intertec and Primedia, where she rose to VP, ancillary products before joining Ascend, which was founded by a trio of Primedia veterans. There, she worked as director of media sales for the events media division before leaving in August.

“I was familiar with AAFP's high standards of excellence, and when I learned of this opening, I had to jump on it,” said Hanaway.

Melton, who has been with AAFP for 20 years, will stay on until January 15 for a smooth transition. Under her direction, American Family Physician has been a reliably strong performer in an ugly market for primary care titles. In 2005, MM&M named the title Medium of the Year as it beat out all others in readership and ad exposures.      

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...